CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Completed · Phase 1

Conditions studied: Cancer

In brief

RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00374179

Run by

Adnexus, A Bristol-Myers Squibb R&D Company

People needed

40

Starts

2006-08-01

Expected to finish

2009-02-01

Last updated by the study team

2009-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Indiana University Cancer Center — Indianapolis, Indiana, United States
• South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States
• Institute for Drug Development — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.